CN101214306A - 一种治疗高血压的中草药 - Google Patents
一种治疗高血压的中草药 Download PDFInfo
- Publication number
- CN101214306A CN101214306A CNA2008100257848A CN200810025784A CN101214306A CN 101214306 A CN101214306 A CN 101214306A CN A2008100257848 A CNA2008100257848 A CN A2008100257848A CN 200810025784 A CN200810025784 A CN 200810025784A CN 101214306 A CN101214306 A CN 101214306A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- blood
- chinese herbal
- herbal medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 32
- 241000411851 herbal medicine Species 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 36
- 244000110343 Elephantopus scaber Species 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 230000001631 hypertensive effect Effects 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 241000219780 Pueraria Species 0.000 claims description 7
- 241000545442 Radix Species 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 22
- 239000002994 raw material Substances 0.000 abstract description 9
- 210000004204 blood vessel Anatomy 0.000 abstract description 8
- 230000006870 function Effects 0.000 abstract description 7
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 2
- 241000208688 Eucommia Species 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 241000488974 Loranthus Species 0.000 abstract 1
- 241000972672 Phellodendron Species 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 241001521901 Tribulus lanuginosus Species 0.000 abstract 1
- 241000157352 Uncaria Species 0.000 abstract 1
- 230000003071 parasitic effect Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 description 26
- 239000008280 blood Substances 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 24
- 208000002173 dizziness Diseases 0.000 description 13
- 239000006187 pill Substances 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 239000007789 gas Substances 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 230000005070 ripening Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010012373 Depressed level of consciousness Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000019395 Lactation disease Diseases 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 210000001369 pituitary-adrenal system Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗高血压的中草药,它由如下重量份的原料药制成:葛根8~12份、丹参10~14份、川芎4~8份、黄柏4~8份、桑寄生10~14份、地胆草3~7份、钩藤13~17份、杜仲8~12份和白蒺藜6~10份。本发明各原料药的功效起协同作用,能够迅速作用于血管,修复损伤的陈旧血管壁,恢复血管弹性,改善动脉硬化,全面调节人体机能,从而能够预防和治疗高血压。
Description
技术领域
本发明涉及一种中草药,具体说是一种治疗高血压的中草药。
背景技术
高血压病是指以人体循环动脉血压升高为主要临床表现的全身性慢性血管病。由于全身细小动脉长期反复痉挛,以及脂类物质在管壁沉着引起管壁硬化,可造成心、脑、肾等重要脏器的缺血性病变。是以头痛、头晕、耳鸣、健忘、失眠、乏力、心悸等一系列神经功能失调的病症为主,导致各种危险并发症,从而形成恶性循环,最终不断引发和加重心脏、血管和各个脏器的病变,所以高血压病的真正危害是,长期的血压增高会损害心脏、脑、肾脏、血管等重要器官,导致这些靶器官功能障碍、衰竭,以及脑卒中、心肌梗塞等致死、致残率很高的心脑血管事件发生。
心脑血管疾病的致痛原理较为复杂,患者多为老年人,其为阴阳失调,营血亏损,血行不畅,其病机主要为“气虚血淤”。
人体是一个气血相依,脏腑相关的有机整体,心脑血管气虚血淤之病变会影响到整体机能,血压增高的实质,是由器官供血不足而造成的,保证体内各个器官正常血液的供求平衡,首先要供给器官所需的气血,才能达到降压的目的。本病之头痛、眩晕、心悸、脉弦等阳亢的实证为标象。
目前,市面上有不少治疗高血压的药物,但效果好的价格比较高,一般的患者难以接受,价格低的效果又不怎么理想。
发明内容
本发明的目的是提供一种效果比较理想、价格低廉的治疗高血压的中草药。
本发明提供的治疗高血压的中草药,其原料药选用葛根、丹参、川芎、黄柏、桑寄生、地胆草、钩藤、杜仲、白蒺藜,是因为:
葛根,味甘微辛,气清香,性凉,主入脾胃经,有发表解肌,升阳透疹,解热生律之功效,用于治疗表热症,麻疹初起,脾虚泄泻,热病口渴,消渴等病症。据现代医学研究,葛根能扩张冠状动脉和脑血管,使其血流量增加;葛根总黄酮能降低心肌耗氧量,葛根有明显的降压作用,还具有抑制血小板凝集作用等。
丹参,苦,微寒,祛瘀止痛,活血通经,清心除烦;丹参能扩张冠状动脉,增加冠脉流量,改善心肌缺血,并能扩张外周血管,改善微循环;有抗凝,促进纤溶,抑制血栓形成的作用,有降高血脂的作用,并有抗纤维化的作用;能提高机体的耐缺氧能力;能促进组织的修复,加速骨折的愈合;还有增强机体的免疫功能,降低血糖及抗肿瘤等作用。
川芎,性温,味辛,行气开郁,祛风燥湿,活血止痛,治风冷头痛旋晕,胁痛腹疼,寒痹筋挛,经闭,难产,产后瘀阻块痛,痈疽疮疡,用于***,经闭痛经,瘕腹痛,胸胁刺痛,跌扑肿痛,头痛,风湿痹痛。此外,《本草汇言》:“川芎,上行头目,下调经水,中开郁结,血中气药,尝为当归所使,非节治血有功,而治气亦神验也,味辛性阳,气善走窜而无阴凝粘滞之态,虽入血分,又能去一切风,调一切气”。川芎能抑制平滑肌收缩,扩张冠状运动,改善心肌缺氧状况及肠系膜的微循环,并能降低心肌耗氧量,降低外周血管阻力,抑制血小板聚集,可预防血栓的形成。
黄柏,苦,寒,清热燥湿,泻火除蒸,解毒疗疮,用于湿热泻痢,黄疸,带下,热淋,脚气,痿辟,骨蒸劳热,盗汗,遗精,疮疡肿毒,湿疹瘙痒;黄柏滋阴降火,用于阴虚火旺,盗汗骨蒸。又《珍珠囊》:“黄柏之用有六:泻膀胱之火,一也;利小便结,二也;除下焦湿肿,三也;痢疾先见血,四也;脐中痛,五也;补肾不足,壮骨髓,六也。”黄柏对血小板有保持作用,还有利胆、利尿、降压等作用。
桑寄生,味苦、甘,补肝肾,强筋骨,祛风湿,安胎,用于风湿痹痛、腰膝酸软、筋骨无力、胎动不安、早期流产、高血压症;具有降压、镇静、利尿作用。能舒张冠状血管,增加冠脉血流量。对脊髓灰质炎有抑制作用。
地胆草,性寒,味苦辛;清热解毒,凉血消肿,止咳利尿;有效降压等作用。
钩藤,性凉,味甘,清热平肝,息风定惊,用于头痛眩晕、感冒夹惊、惊痢抽搐、妊娠子痢、高血压症;
杜仲,甘微辛,温补肝肾,强筋骨,安胎,治腰脊酸疼,足膝痿弱,小便余沥,阴下湿痒,胎漏欲堕,胎动不安,高血压。杜仲有较好的降压作用,并能减少胆固醇的吸收。有一定的镇痛以及利尿作用,能增强机体的免疫功能。
白蒺藜,苦辛,微温。平肝解郁,祛风明目。治头痛、眩晕、胁痛、缺乳、风疹、目赤肿翳。除此之外,对机体某些衰老,退化性变化有一定抑制作用;有阻止动脉、心肌及肝脏的脂质沉着作用;有降血压作用。
本发明本着以“益血活血”为宗旨,取其“气不虚不阻,血得气而不滞”为本质。将它们配伍使得各原料药的功效起协同作用,能够迅速作用于血管,修复损伤的陈旧血管壁,恢复血管弹性,改善动脉硬化,全面调节人体机能,从而能够预防和治疗高血压。
为了取得更好的疗效,本发明还可含有首乌、白芍、当归、麦冬、甘草。其中:
首乌,补肝肾,益精血,壮筋骨,有降低血脂、减心率、增强机体抗寒能力、促进红细胞生成等作用。能减轻动脉内膜的斑块形成和脂质沉积,从而可以缓解动脉粥样硬化的形成;可增强免疫功能,还有强壮神经,健脑益智作用。
白芍,苦酸,凉,具有养血柔肝,缓中止痛,敛阴收汗。治胸腹胁肋疼痛,泻痢腹痛,自汗盗汗,阴虚发热,***,崩漏,带下。白芍含有芍药苷,芍药苷有很好的解痉作用,并有一定的镇静、镇痛、抗惊厥、降压、扩张血管等作用;有增强心肌营养性血流量的作用。
当归,辛、微苦,补血活血,调经止痛,润肠通便。用于血虚萎黄,眩晕心悸,***,经闭痛经,虚寒腹痛,肠燥便秘,风湿痹痛,跌扑损伤,痈疽疮疡。当归有抗血小板凝集和抗血栓作用;有降低血脂功效;能增强机体的免疫功能;能促进肝细胞再生和恢复肝脏某些功能的作用;还有镇静、镇痛、扩炎的作用。
麦冬,甘、微苦,微寒,养阴生津,润肺清心。用于肺燥干咳,虚痨咳嗽,津伤口渴,心烦失眠,内热消渴,肠燥便秘,咽白喉。能提高机体的免费功能;能增强垂体肾上腺皮质***作用,提高机体适应性;有抗心律失常和扩张外周血管作用;有降低血糖作用;对多种细菌有不同程度的抑制作用,能提高耐缺氧能力。
甘草,味甘,有解毒、祛痰、止痛、解痉以至抗癌等药理作用。甘草得中和之性,有调补之功,故毒药得之解其毒,刚药得之和其性,表药得之助其外,下药得之缓其速。随气药入气,随血药入血,无往不可,故称国老。
以上十四味药组合,可以益诸脏之气,活一身之血,使气旺血活,心脉得通,脑以得养,从而达到扩张心脑血管、增加血流量、降血压和益心健脑的功能,预防和治疗高血压的效果更佳。
本发明治疗高血压的中草药,其原料药组分的含量是经过本发明人在大量的临床实践中得出来的,且在下述重量份范围的疗效都是比较理想的:
葛根8~12份、丹参10~14份、川芎4~8份、黄柏4~8份、桑寄生10~14份、地胆草3~7份、钩藤13~17份、杜仲8~12份和白蒺藜6~10份。
优选为:葛根10份、丹参12份、川芎6份、黄柏6份、桑寄生12份、地胆草5份、钩藤15份、杜仲10份和白蒺藜8份。
如果还含有首乌、白芍、当归、麦冬、甘草,其重量份是:葛根8~12份、丹参10~14份、川芎4~8份、黄柏4~8份、桑寄生10~14份、地胆草3~7份、钩藤13~17份、杜仲8~12份、白蒺藜6~10份、首乌8~12份、白芍8~12份、当归10~14份、麦冬6~10份和甘草4~8份。
优选为:葛根10份、丹参12份、川芎6份、黄柏6份、桑寄生12份、地胆草5份、钩藤15份、杜仲10份、白蒺藜8份、首乌10份、白芍10份、当归12份、麦冬8份和甘草6份。
本发明治疗高血压的中草药,可采用中药制剂的常规方法制备成任何常规内服制剂。例如可以将上述原料药制成散剂,用水冲服,或者将上述原料药一起水煎,服用煎液,还可将上述原料药用水或常规溶剂如乙醇等提取活性成分后,加入制备不同剂型时所需的各种常规辅料,按常规中药制剂方法制备成任何一种口服剂型,如丸剂、片剂、口服液等。
本发明人采用下述方法制得该中草药:
将各原料药粉碎至120目细粉,进行熟化灭菌,制得散剂。
服用方法:每次25克,用水冲服。
经临床应用,证明该中草药在治疗高血压的效果非常显著。
以下是本发明的药用效果:
例一:患者男62岁,因7年前中风留下行动慢、血压高、难入睡等症状,要长期服用降压片。刚开始服本发明的药物时,感觉比较好,过了几天好像有点感冒,血压不稳定,要服用降压片,后来每周服药一次,经服用三次后血压已经稳定,不用再服西药降压片,感觉手脚灵活,行动方便轻快,以前要30分钟才能走到的路程,现在只需10分钟。睡眠好转。为了巩固疗效患者再服有三次药,至今三年多不用服任何降压药,血压稳定在正常范围内。
例二、52岁男,患者因脑动脉硬化,血压高难入睡等,经常饮一种说是治动脉硬化的酒和各种降压药,已经长达七年时间,经常感觉头晕,经测血压高达180。后经服本发明药物三天,每天一次,刚开始感觉好转,头不觉得那么重那么晕了,而血压却不稳定,有今天高明天底到正常值等现象出现。后又每周服一次,测得最高血压从180降至最高160,感觉有点头晕就服一次,共服药8至10次,头晕、难入睡等症状消失后,就算血压有一点高,头不晕也不用服降压药,直至一年多后,复测血压已在正常范围内130/80毫米汞柱,不再服任何降压药。
例三、60岁男,因一年前中风血压高而服降压片,后服本发明药物三次,每周服一次,血压已恢复正常值范围内,这时停服一切中西降压药,血压稳定,但过一年之后,感觉有一点头晕症状出现,所以继续服本发明药物五次,每周一次,头晕现象马上消失。至今二年多不用服任何降压药物,血压在正常范围内。
例四、病人65岁,女,因突然晕倒地下,送医院救治,测血压高,要经常看病,每天都要服降压药,已有二年多,经服本发明药物二次,测得左手血压已正常,右手测血压时,看见血压表在跳动,时高时底不稳定,再服一次药后,即共服三次,达一年时间不用服任何降压药物,血压正常。一年后,又要每天服降压片,吃了二个月各种降压片,不见好转。但又不能停服西药,后再服用本发明药物一至二次,发现有呕吐的现象,就不再服用本发明药物,但又不用每天服降压片,感觉三天至五天才服一次降压片也可以了,后直至不舒服和头晕才服降压片,平时一般不再服降压片了,至今已大半年。
例五、52岁男,因有中风现象,血压少许偏高,送医院救治,入院至第二天,患者情况越来越严重,前天扶着还能走路,今天手脚已不能动了,神志不清,半睡半醒,该院长说会形成脑血管阻塞,比较难治理,要花很多钱也不知能不能治好。这时给患者服用本发明药物,即入医院第二天下午4点钟服药至晚上7点钟已见患者渐渐好转了。手脚能动,神志清醒,第二天再服用本药,当天就可以出院,至服用三次,每周一次,患者基本已正常,就是性格有点爆燥,之后再服三次患者一切已康复、血压正常。现如正常人一样生活了二年半了。
具体实施方式
实施例一:
按如下重量称取原料药:葛根10Kg、丹参12Kg、川芎6Kg、黄柏6Kg、桑寄生12Kg、地胆草5Kg、钩藤15Kg、杜仲10Kg和白蒺藜8Kg。
制备方法:将上述原料药粉碎至120目细粉,进行熟化灭菌,制得散剂。
实施例二:
按如下重量称取原料药:葛根10Kg、丹参12Kg、川芎6Kg、黄柏6Kg、桑寄生12Kg、地胆草5Kg、钩藤15Kg、杜仲10Kg、白蒺藜8Kg、首乌10Kg、白芍10Kg、当归12Kg、麦冬8Kg和甘草6Kg。
制备方法:将上述原料药粉碎至120目细粉,进行熟化灭菌,制得散剂。
Claims (4)
1.一种治疗高血压的中草药,其特征是它由如下重量份的原料药制成:
葛根8~12份、丹参10~14份、川芎4~8份、黄柏4~8份、桑寄生10~14份、地胆草3~7份、钩藤13~17份、杜仲8~12份和白蒺藜6~10份。
2.根据权利要求1所述的一种治疗高血压的中草药,其特征是它由如下重量份的原料药制成:
葛根10份、丹参12份、川芎6份、黄柏6份、桑寄生12份、地胆草5份、钩藤15份、杜仲10份和白蒺藜8份。
3.根据权利要求1所述的一种治疗高血压的中草药,其特征是它还含有如下重量份的原料药:
首乌8~12份、白芍8~12份、当归8~12份、麦冬8~12份和甘草8~12份。
4.根据权利要求3所述的一种治疗高血压的中草药,其特征是它由如下重量份的原料药制成:
葛根10份、丹参12份、川芎6份、黄柏6份、桑寄生12份、地胆草5份、钩藤15份、杜仲10份、白蒺藜8份、首乌10份、白芍10份、当归12份、麦冬8份和甘草6份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100257848A CN101214306B (zh) | 2008-01-08 | 2008-01-08 | 一种治疗高血压的中草药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100257848A CN101214306B (zh) | 2008-01-08 | 2008-01-08 | 一种治疗高血压的中草药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101214306A true CN101214306A (zh) | 2008-07-09 |
CN101214306B CN101214306B (zh) | 2010-10-06 |
Family
ID=39620854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100257848A Expired - Fee Related CN101214306B (zh) | 2008-01-08 | 2008-01-08 | 一种治疗高血压的中草药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101214306B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101773554A (zh) * | 2010-03-18 | 2010-07-14 | 鲍旭刚 | 一种治疗高血压的药物及其制备方法 |
CN101884674A (zh) * | 2010-06-25 | 2010-11-17 | 王付华 | 预防和治疗高血压的中药 |
CN102068605A (zh) * | 2010-03-17 | 2011-05-25 | 谭元生 | 一种用于治疗高血压的中药组合物 |
CN103816515A (zh) * | 2014-03-05 | 2014-05-28 | 济南伟传信息技术有限公司 | 一种治疗高血压的中药 |
CN104800600A (zh) * | 2015-04-13 | 2015-07-29 | 孙泽刚 | 一种治疗高血压的药物 |
CN105287967A (zh) * | 2015-10-30 | 2016-02-03 | 重庆市洪欣食用菌有限公司 | 治疗高血压的中药组合物及其草药汤剂的制备方法 |
CN108635497A (zh) * | 2018-07-30 | 2018-10-12 | 佛山科学技术学院 | 一种治疗高血压的中药制剂及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100467037C (zh) * | 2004-11-05 | 2009-03-11 | 贺泉霖 | 一种治疗高血压的药物及其制备方法 |
-
2008
- 2008-01-08 CN CN2008100257848A patent/CN101214306B/zh not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102068605A (zh) * | 2010-03-17 | 2011-05-25 | 谭元生 | 一种用于治疗高血压的中药组合物 |
CN101773554A (zh) * | 2010-03-18 | 2010-07-14 | 鲍旭刚 | 一种治疗高血压的药物及其制备方法 |
CN101884674A (zh) * | 2010-06-25 | 2010-11-17 | 王付华 | 预防和治疗高血压的中药 |
CN103816515A (zh) * | 2014-03-05 | 2014-05-28 | 济南伟传信息技术有限公司 | 一种治疗高血压的中药 |
CN103816515B (zh) * | 2014-03-05 | 2016-05-04 | 菏泽海诺知识产权服务有限公司 | 一种治疗高血压的中药 |
CN104800600A (zh) * | 2015-04-13 | 2015-07-29 | 孙泽刚 | 一种治疗高血压的药物 |
CN105287967A (zh) * | 2015-10-30 | 2016-02-03 | 重庆市洪欣食用菌有限公司 | 治疗高血压的中药组合物及其草药汤剂的制备方法 |
CN108635497A (zh) * | 2018-07-30 | 2018-10-12 | 佛山科学技术学院 | 一种治疗高血压的中药制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101214306B (zh) | 2010-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103520654B (zh) | 一种用于治疗膝骨关节炎的中药组合物及其制备方法 | |
CN101347528B (zh) | 抗心脑血管疾病的中药组合物 | |
CN101214306B (zh) | 一种治疗高血压的中草药 | |
CN104146261B (zh) | 一种妇女更年期的中药保健品及其制备方法 | |
CN103816498A (zh) | 一种治疗睡眠障碍的中药混合物 | |
CN102579708B (zh) | 一种壮阳补肾健肝肺的中药 | |
CN104666579A (zh) | 一种治疗膝关节滑膜炎的中药组合物及其制备方法 | |
CN102366541B (zh) | 一种治疗消渴病的中药组合物 | |
CN103316224A (zh) | 具有补肝肾、益精血、健脑明目的中药制剂 | |
CN101095923B (zh) | 一种治疗***的中药 | |
CN104740268A (zh) | 一种治疗冠心病的中药组合物 | |
CN105056133A (zh) | 一种用于治疗纤维肌痛综合症的中药丸剂及制备方法 | |
CN104721628A (zh) | 一种用于脑震荡康复治疗的中药药丸及制备方法 | |
CN104056119A (zh) | 一种保健酒及其制备方法 | |
CN102451340A (zh) | 一种治疗痛风的中药足浴方剂 | |
CN105106749A (zh) | 一种普外科治疗痔疮的中药组合物 | |
CN105535486A (zh) | 用于产后肝郁气滞型缺乳的药物及其制备方法 | |
CN104001073A (zh) | 一种治疗脾气虚弱型月经先期的中药组合物及其制备方法 | |
CN102743550B (zh) | 加速骨折手术后愈合速度的药物组合物、制备方法及应用 | |
CN104189714A (zh) | 一种治疗冠心病的中药胶囊 | |
CN104800610A (zh) | 一种治疗帕金森病的中药制剂及其制备方法 | |
CN104667183A (zh) | 治疗湿热邪滞型化脓性骨髓炎的药物制剂及其制备方法 | |
CN102895352B (zh) | 药物组合物及其用途 | |
CN106421225A (zh) | 一种补肾壮骨的中药配方 | |
CN105560911A (zh) | 一种治疗高血压的中药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101006 Termination date: 20130108 |